Nasopharyngeal carcinoma in Asia, especially in China's Southern China region, early nasopharyngeal carcinoma radiotherapy can achieve bette
Nasopharyngeal carcinoma in Asia, especially in China's Southern China region, early nasopharyngeal carcinoma radiotherapy can achieve better curative effect, but the curative effect of radiotherapy combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma need to be further improved, and targeted therapy will become a new therapy to improve cancer patients. At present, the effect of EGFR antagonist cetuximab in treatment of head and neck neoplasms has been confirmed by a number of studies, results of a multicenter study showed that cetuximab combined with carboplatin for metastatic nasopharyngeal carcinoma and platinum chemotherapy failure recurrence has good efficacy and safety standards; combined with concurrent cetuximab chemotherapy, can to improve the local control rate of patients with locally advanced nasopharyngeal carcinoma, tumor free survival and overall survival, more research is needed to confirm the results. Sponsored by the Zhongshan University cancer center, 8 hospitals nationwide to participate in a multicenter study of ENCORE of IMRT in cisplatin (IMRT) on the basis of radiotherapy for locally advanced nasopharyngeal carcinoma in order to explore the efficacy of cetuximab and safety, showing good prospects, the results announced in 2010 the American Society of Clinical Oncology (ASCO) annual meeting. A total of 100 patients with locally advanced nasopharyngeal carcinoma (NPC) were enrolled in the ENCORE study, which is the world's largest group of patients with EGFR in the treatment of locally advanced nasopharyngeal carcinoma (NPC). The primary end point was the local tumor control rate at the end of the 3 month after treatment, and the secondary outcomes were remission rates, long-term local control, survival, and safety. The preliminary results of the ENCORE study showed that cetuximab combined with IMRT+ cisplatin was effective in the treatment of locally advanced nasopharyngeal carcinoma, and the local control rate was 100% after treatment for up to 3 months. The patient was well tolerated and well tolerated. All patients completed the radiotherapy plan. 99% of the patients received cisplatin chemotherapy and cetuximab. As of November 30, 2009, the median follow-up time was 330 days, with no local recurrence (including nasopharyngeal and positive lymph nodes), and distant metastasis in the follow-up period of 4 cases. 5 patients died (5%), of which 2 died of tumor progression. Cetuximab is currently the only target for the treatment of locally advanced and recurrent and / or metastatic head and neck squamous cell carcinoma (EMEA) approved by us FDA and eu. The publication of the results of the ENCORE study will provide new treatment options for patients with locally advanced nasopharyngeal carcinoma.